TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
AstraZeneca at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
AstraZeneca takes part in 4 sessions at TIDES Europe 2026 in Amsterdam. Its sessions span oligonucleotide and peptide manufacturing, from rethinking the green credentials of oligonucleotide production to fragment-based peptide synthesis routes that enable a move to liquid phase. It also addresses diastereomeric control in phosphorothioate siRNAs and peptide-targeted delivery of oligonucleotide therapeutics.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Find decision makers at AstraZeneca
Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction